Articles by Sandra Kitchen
Sandra has been avidly involved in watching the stock market and writing about the stock movements that interest investors. She specializes in small and mid-cap Biotech stocks with a main focus on public companies awaiting FDA approval of new drugs and/or products. living in New York, with her family and pets, she stays up on the latest news from the New York Stock Exchange and the FDA. Her goal is to bring the news to investors from a fresh, unbiased, pure research point of view.
Novo Nordisk A/S (ADR) (NYSE:NVO) has made an announcement that their diabetes treatment Liraglutide cuts weight and reduces health risks in obese non-diabetics.
You can purely call it a Microsoft magic that despite their sales have gone down, their shares on the market have soared higher than what the analysts had expected.
Human Genome Sciences Inc made an announcement that their experimental lupus drug has shown positive results and works faster that what they had expected from the drug.
It was a good closing day for AstraZeneca as they announced that the Food and Drug Administration has approved Crestor (rosuvastatin calcium) for use in pediatric patients suffering from heterozygous familial hypercholesterolemia (HeFH).
Progenics Pharmaceuticals have announced that they have entered an agreement with Wyeth Pharmaceuticals under which they will be regaining all the worldwide rights to the Relistor franchise from Wyeth Pharmaceuticals.
Sanofi-Aventis has recently been very close to MA-based Dyax. Recently Sanofi-Aventis had made an announcement that they have entered into an agreement with Fovea Pharmaceuticals for US$ 540 million to partner with the pharmaceutical giant …
On a late Friday afternoon, shares of Savient Pharmaceuticals bounced back as analysts for Oppenheimer and Co. raised his views on Savient Pharmaceuticals and its new chronic gout drug candidate Krystexxa.
Hospira Inc and Celltrion Healthcare Inc have signed a Business Cooperation Agreement which outlines the business terms of a future distribution agreement in countries like United States of America, Europe, Canada, Australia and New Zealand …
On an early Tuesday afternoon, MannKind Corporation announced that they do not expect to find any marketing partner for their inhaled insulin drug candidate Afresa in 2009. The news from MannKind Corporation quickly brought down …
It was a good Monday morning for Endo Pharmaceutical Holdings Inc as their shares rise in the stock market after an analysts upgraded the stock predicting better third quarter and full year results for Endo. …
